November 2020
Volume 61, Issue 13
Open Access
Retraction  |   November 2020
Retraction
Investigative Ophthalmology & Visual Science November 2020, Vol.61, 18. doi:https://doi.org/10.1167/iovs.61.13.18
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Retraction. Invest. Ophthalmol. Vis. Sci. 2020;61(13):18. doi: https://doi.org/10.1167/iovs.61.13.18.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Retraction of: “Effect of Timolol on Optineurin Aggregation in Transformed Induced Pluripotent Stem Cells Derived From Patient With Familial Glaucoma” by Satoshi Inagaki, Kazuhide Kawase, Michinori Funato, Junko Seki, Chizuru Kawase, Kazuki Ohuchi, Tsubasa Kameyama, Shiori Ando, Arisu Sato, Wataru Morozumi, Shinsuke Nakamura, Masamitsu Shimazawa, Daisuke Iejima, Takeshi Iwata, Tetsuya Yamamoto, Hideo Kaneko and Hideaki Hara (Invest Ophthalmol Vis Sci. 2018;59(6):2293–2304), https://doi.org/10.1167/iovs.17-22975
After publication of our article, “Effect of Timolol on Optineurin Aggregation in Transformed Induced Pluripotent Stem Cells Derived From Patient With Familial Glaucoma,” we became aware that blood samples were collected after obtaining informed consent from the patients but without receiving ethical approval from the ethics committee at the institute where they were collected. On the other hand, the ethical approvals were obtained at the other institutes where the induced pluripotent stem cells (iPS) was generated and experiments were conducted. 
Because of these wrong ethical procedures, we wish to retract this article and apologize for the confusion. 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×